Nalaganje...
Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer
BACKGROUND: Targeting BRAF V600E mutation has been proven effective in the treatment of several types of cancer. In endometrial adenocarcinoma, the BRAF V600E mutation has been rarely reported. Whether targeting BRAF oncogene may represent a plausible therapeutic strategy for the rare patients with...
Shranjeno v:
| izdano v: | Exp Hematol Oncol |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5223353/ https://ncbi.nlm.nih.gov/pubmed/28078189 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-016-0061-2 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|